Primary Solid Pseudopapillary Tumor of the Ovary: A Case Report and Review of the Literature

被引：1

作者：

Lee, Juhun ^{[1
]}

Song, Seung Ho ^{[2
]}

Lee, In Hee ^{[3
]}

Kim, Dong Ja ^{[4
]}

Lee, Hyun Jung ^{[1
]}

机构：

[1] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Obstet & Gynecol, Daegu 41944, South Korea

[2] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Surg, Daegu 41944, South Korea

[3] Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Hematol Oncol, Daegu 41404, South Korea

[4] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Forens Med, Daegu 41404, South Korea

来源：

JOURNAL OF CLINICAL MEDICINE | 2024年 / 13卷 / 10期

关键词：

solid pseudopapillary tumor; ovarian cancer; rare tumor; CTNNB1; BETA-CATENIN MUTATION; NEOPLASM; PANCREAS; ORIGIN; SPN;

D O I：

10.3390/jcm13102791

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction: Solid pseudopapillary neoplasms (SPNs) are rare and mainly originate from the pancreas. SPNs originating from the ovary (SPN-O) are extremely rare, and only 13 cases have been reported in the English literature since 2010. Case: We report a 31-year-old woman with SPN-O accompanied by multiple metastases in the abdominal cavity. The patient underwent staging surgery and cytoreduction. Furthermore, the multidisciplinary board decided on adjuvant chemotherapy with an FP regimen (fluorouracil plus cisplatin) because a microscopic metastasis was discovered in the peritoneum near the appendix. Next-generation sequencing showed some pathologic mutations of oncogenes/cancer-associated genes, including CTNNB1 and TP53. This is the fourteenth case of SPN-O and the first one to demonstrate the TP53 pathogenic mutant variant in SPN-O. The patient showed 8 months of disease-free survival until February 2024. Conclusion: The combination of R0 cytoreduction with FOLFIRI chemotherapy appears to be an effective and feasible treatment option.

引用

页数：9

共 26 条

[1] Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor β-catenin mutations [J].